@FiercePharma
www.fiercepharma.com RevMed’s Rasonque debut nets ‘eye-popping’ $198M in 5 weeks, even as exec tempers expectations After roughly one month on the market, Revolution Medicines’ RAS inhibitor daraxonrasib is living up to its much-hyped potential, with an initial sales performance that more than one group of analy |... 
www.fiercepharma.com AstraZeneca said to offer $10B to acquire Rhythm, analysts whisper of a bidding war AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping making big bets. | AstraZeneca has made a roughly $10 billion offer to... 
www.fiercepharma.com Novo catches Wegovy pill tailwind in Q3 as CEO eyes new launch horizons in 2027 With a modest improvement to guidance and rosy launch expectations for 2027 girding a solid quarter for its GLP-1 franchise, Novo appears to be gradually winning back the confidence of some of its |... 
www.fiercepharma.com Madrigal’s former clinical development head files whistleblower lawsuit alleging Rezdiffra safety... Amid surging sales of Rezdiffra, Madrigal Pharmaceuticals is facing a whistleblower lawsuit alleging that senior leadership censored serious liver-injury data related to the world’s first approved |... 
www.fiercepharma.com Madrigal’s Rezdiffra storms past blockbuster milestone as CEO hails ‘accelerating’ MASH market To Bill Sibold, “it’s hard to find a more attractive growth opportunity in biotech” than metabolic dysfunction-associated steatohepatitis (MASH). | To Madrigal CEO Bill Sibold, “it’s hard to find a... 